We read with great interest the recent HEPATOLOGY article by Starlinger et al., 1 in which they proved that low preoperative platelet-derived 5-hydroxytryptamine (5-HT; serotonin; <73 ng/mL) would result in high incidence of postoperative liver dysfunction and morbidity. It seemed that 5-HT was a beneficial factor in patients with liver tumor. Thus, they concluded "involvement of 5-HT might represent a novel therapeutic target to accelerate [liver regeneration] LR after hepatectomy."We want to point out that in contrast to the data by Starlinger et al., Soll et al.2 highlighted that 5-HT could promote cell survival and growth of hepatocellular carcinoma (HCC) cells by the activation of the 5-HT2B receptor. In addition, they found that there was a significant decrease in hepatic tumor formation rate in tryptophan hydroxylase 1-deficient mice (lacking peripheral 5-HT) chronically fed with CCl 4 . In another article, Buergy et al. 3 demonstrated that thrombocytosis (high 5-HT level) at the time of diagnosis was associated with a shorter survival in many solid tumors, including HCC.In addition to the relationship between 5-HT and promotion of HCC, other reports investigated the relationship between 5-HT and hepatitis virus infection and subsequent cirrhosis, which are predominant prognostic factors for HCC. Lang et al. 4 found that treatment with 5-HT in infected mice aggravated liver damage by delaying virus clearance. In contrast, mice lacking serotonin accelerated virus clearance and reduced liver damage. Moreover, the article by Ruddell et al. 5 pointed out that 5-HT played a profibrogenic role by mediating proliferation and apoptosis of hepatic stellate cells.In conclusion, 5-HT can produce both beneficial and detrimental effects in basic liver diseases as well as HCC. Therefore, more clinical and experimental studies are needed to determine the complicated relationships between 5-HT and HCC before considering it as a novel therapeutic target. Author names in bold designate shared co-first authorship.
Reply:We want to thank Dr. Pang et al. for their interest and important remarks regarding our article. In our recently published investigation we reported intraplatelet (IP) 5-hydroxytryptamine (5-HT) levels to predict postoperative liver dysfunction and morbidity in patients undergoing liver resection. Based on its striking association with clinical outcome after partial hepatectomy, we thus proposed that IP 5-HT might represent a therapeutic target to accelerate liver regeneration after liver resection.1 It should be stressed that we did not evaluate the effects of IP 5-HT on tumor development or progression or its effects on viral hepatitis. Pang et al. point to a relevant issue with the potential use of 5-HT which may appear like a double-edged sword for the liver, as also recently discussed by Lesurtel et al. in more detail. 2 We agree with Pang et al. that further research is required to determine whether perioperative modification of IP 5-HT levels is of overall benefit in patients undergoing liver ...